A detailed history of Morgan Stanley transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,398,918 shares of TARS stock, worth $79.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,398,918
Previous 1,957,688 22.54%
Holding current value
$79.1 Million
Previous $39.6 Million 119.96%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$19.61 - $39.22 $8.65 Million - $17.3 Million
441,230 Added 22.54%
2,398,918 $87.2 Million
Q4 2023

Feb 13, 2024

BUY
$12.98 - $20.73 $24.5 Million - $39.1 Million
1,883,869 Added 2552.01%
1,957,688 $39.6 Million
Q3 2023

Nov 15, 2023

BUY
$14.75 - $24.62 $350,135 - $584,429
23,738 Added 47.4%
73,819 $1.31 Million
Q2 2023

Aug 14, 2023

BUY
$11.57 - $19.63 $206,941 - $351,102
17,886 Added 55.56%
50,081 $904,000
Q1 2023

May 15, 2023

BUY
$11.92 - $16.27 $87,468 - $119,389
7,338 Added 29.52%
32,195 $404,000
Q4 2022

Feb 14, 2023

BUY
$14.12 - $18.72 $8,288 - $10,988
587 Added 2.42%
24,857 $364,000
Q3 2022

Nov 14, 2022

SELL
$14.08 - $18.5 $152,753 - $200,706
-10,849 Reduced 30.89%
24,270 $416,000
Q2 2022

Oct 27, 2022

BUY
$11.08 - $19.08 $264,900 - $456,164
23,908 Added 213.25%
35,119 $512,000
Q2 2022

Aug 15, 2022

BUY
$11.08 - $19.08 $264,900 - $456,164
23,908 Added 213.25%
35,119 $512,000
Q1 2022

Oct 27, 2022

SELL
$14.49 - $24.28 $346,426 - $580,486
-23,908 Reduced 68.08%
11,211 $188,000
Q1 2022

May 13, 2022

SELL
$14.49 - $24.28 $391 - $655
-27 Reduced 0.24%
11,211 $188,000
Q4 2021

Feb 14, 2022

SELL
$21.21 - $29.68 $366,763 - $513,226
-17,292 Reduced 60.61%
11,238 $253,000
Q3 2021

Nov 15, 2021

BUY
$21.45 - $29.22 $611,968 - $833,646
28,530 New
28,530 $615,000

Others Institutions Holding TARS

About Tarsus Pharmaceuticals, Inc.


  • Ticker TARS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,658,500
  • Market Cap $879M
  • Description
  • Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...
More about TARS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.